Protocol Reference
CJC-1295 (DAC)
CJC-1295 — phase 1 trial administration as published
Summarise how CJC-1295 was administered in the published phase 1 human research, and what those studies measured.
Not FDA ApprovedReviewed September 1, 2026
No established human dosing protocol exists for this compound. What follows describes the research context only — the conditions under which the compound has been studied, usually in animals or in vitro.
Research Context
- Source of this information
- Phase 1 research established pharmacokinetics and biochemical response only. Development was discontinued before efficacy trials.
- Evidence level
- Grade C — phase 1 human pharmacodynamic studies of biochemical endpoints
- Population studied
- Healthy adult volunteers.
- Duration studied
- Single-dose and short multiple-dose studies over weeks.
- Route reported
- Subcutaneous injection in the published studies
Protocol as Reported
- 01Published phase 1 work administered single ascending subcutaneous doses expressed per kilogram of body weight, with GH and IGF-1 sampling over subsequent days.
- 02Multiple-dose research administered injections at weekly or twice-weekly intervals, consistent with the albumin-bound half-life.
- 03Endpoints were GH and IGF-1 concentrations, not body composition, strength or recovery.
Adverse Events Reported
- Injection-site reactions, flushing and headache reported in early trials.
- Sustained IGF-1 elevation raises unresolved concerns regarding glucose tolerance, oedema, arthralgia and neoplasia.
Limitations
- No efficacy outcome data exist for any indication.
- No approved label defines a clinical protocol, and clinical development was discontinued.
- Community combination protocols with secretagogues have no controlled human evidence.
Sources
- Phase 1 trial2006
Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295 in healthy adults
Journal of Clinical Endocrinology & Metabolism
Educational reference only. Peptide Atlas does not provide medical advice or individualised dosing guidance, and nothing on this page should be used to guide personal use.